Vir Biotechnology, Inc. VIR R2KR3KPHARMA
Company Overview
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Why Investors Should Care
Revenue has grown at a 49.2% CAGR over the past five years.
Operating margin of 30.7% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Dec 2025 Revenue of $66.52M (+4.4% YoY); net profit $-437.99M.
- 5-Year Trend Long-term compounding — revenue CAGR 49.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 49.21% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +149.12% |
| 6 Months: | +19.21% |
| 3 Months: | +31.62% |
| 1 Month: | +29.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 49.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VIR Vir Biotechnology, Inc. R2KR3KPHARMA | 11.38 | -6.43 | $1.93B | 0.00% | -52.69% | -26.08% | 49.21% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.38M | 3.08M | 2.38M | - | 1.79M | 1.03M | -65.00K | 63.76M | -41.00K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 684.00K | 0 | 11.00K | -11.00K | 26.00K | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.59M | 1.79M | 1.02M | -54.00K | 63.73M | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 141.35M | 119.61M | 173.39M | 111.66M | 132.25M | - |
| Operating Income | - | - | -34.35M | - | -30.77M | -35.77M | -47.68M | - | -71.91M | -29.05M | -87.61M | - | -158.63M | 61.02M | -53.38M | 1.01B | -225.22M | 194.96M | -143.37M | -215.19M | -186.73M | -80.08M | -158.63M | -231.30M | - | -139.56M | -118.59M | -173.44M | -47.92M | -132.29M | 73.47M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -136.69M | -115.67M | -170.44M | -45.02M | -129.48M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -120.95M | -110.79M | -162.97M | -43.06M | -125.53M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.00K | 170.00K | 168.00K | -137.00K | 170.00K | - |
| Net Income | -31.59M | -24.45M | -33.46M | -26.39M | -28.67M | -33.93M | -48.31M | -63.77M | -77.24M | -31.17M | -84.61M | -105.65M | -168.91M | 61.81M | 110.43M | 518.62M | -76.49M | 175.31M | -140.96M | -194.78M | -163.41M | -65.28M | -138.38M | -213.72M | - | -120.97M | -110.96M | -163.14M | -42.92M | -125.69M | 80.08M |
| Diluted EPS | - | - | - | - | -3.19 | -3.64 | -4.60 | -0.71 | -0.71 | -0.27 | -0.67 | -0.83 | -1.32 | 0.46 | 0.82 | 3.85 | -0.58 | 1.30 | -1.06 | -1.45 | -1.22 | -0.48 | -1.02 | -1.56 | - | -0.88 | -0.80 | -1.17 | -0.31 | -0.85 | 0.47 |
| R&D Expense | - | - | 29.84M | - | 25.87M | 29.80M | 39.86M | - | 64.98M | 79.65M | 70.68M | - | 134.87M | 86.13M | 98.67M | 90.23M | 115.08M | 114.17M | 157.64M | 168.08M | 145.03M | 100.12M | 105.11M | 195.18M | - | 118.64M | 97.51M | 151.46M | - | 108.92M | 135.28M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.71M | 10.67M | 8.09M | 76.37M | 1.10B | 1.58B | 39.49M | 63.71M | 66.52M |
| Cost of Revenue | - | - | - | - | - | 146.32M | 2.77M | 845.00K | 26.00K |
| Gross Profit | - | - | - | - | - | 1.43B | 36.73M | 62.87M | 66.49M |
| Operating Expenses | - | - | - | - | - | 601.09M | 707.48M | 615.04M | 546.00M |
| Operating Income | -81.50M | -118.69M | -177.98M | -296.98M | 420.75M | 833.07M | -670.75M | -552.17M | -479.51M |
| EBITDA | - | - | - | - | - | 839.85M | -651.29M | -537.61M | -467.83M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | 754.28M | -628.19M | -523.11M | -437.77M |
| Tax Provision | - | - | - | - | - | 238.44M | -13.08M | -1.15M | 217.00K |
| Net Income | -69.85M | -115.88M | -174.68M | -298.67M | 528.58M | 515.84M | -615.06M | -521.96M | -437.99M |
| Diluted EPS | - | - | -5.76 | -2.51 | 3.96 | 3.83 | -4.59 | -3.83 | -3.16 |
| R&D Expense | 62.51M | 100.23M | 148.47M | 302.41M | 448.01M | 474.65M | 579.72M | 506.50M | 455.97M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 191.60M | 512.07M | 918.76M | - | 2.80B | 1.92B | 1.40B | 1.00B |
| Current Assets | - | - | - | - | - | - | 2.52B | 1.59B | 1.04B | 514.08M |
| Cash & Equivalents | - | 187.92M | 47.60M | 109.33M | 436.57M | - | 848.63M | 241.58M | 222.95M | 232.19M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 773.08M | 0 | - | - | - |
| Total Liabilities | - | - | 61.64M | 88.13M | 201.91M | - | 724.12M | 328.82M | 248.43M | 237.55M |
| Current Liabilities | - | - | 39.91M | 59.21M | 99.06M | - | 511.03M | 175.41M | 119.66M | 92.81M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 127.97M | 124.54M | 97.89M | 97.85M |
| Total Equity | -7.97M | -68.92M | -179.18M | 423.94M | 716.85M | - | 2.08B | 1.59B | 1.15B | 765.28M |
| Shares Outstanding | - | - | - | - | - | - | 133.24M | 134.78M | 136.96M | 139.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -66.38M | -94.10M | -129.63M | -190.94M | - | 1.66B | -778.78M | -446.35M | -391.78M |
| Investing Cash Flow | -29.99M | -60.44M | -256.16M | -9.86M | - | -1.19B | 164.63M | 499.37M | 310.37M |
| Financing Cash Flow | 271.18M | 24.98M | 449.24M | 529.47M | - | 34.76M | 7.48M | 4.39M | 3.79M |
| Capital Expenditure | -2.74M | -8.19M | -8.94M | -6.55M | - | -68.01M | -21.57M | -7.30M | -4.83M |
| Free Cash Flow | -69.12M | -102.29M | -138.57M | -197.49M | - | 1.60B | -800.36M | -453.65M | -396.61M |
| Net Change in Cash | - | - | - | - | - | 504.55M | -606.68M | 57.40M | -77.62M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 90.7% | 93.0% | 98.7% | 100.0% |
| Operating Margin % | -3,009.5% | -1,112.6% | -2,199.7% | -388.9% | 38.4% | 52.7% | -1,698.3% | -866.7% | -720.9% |
| Net Margin % | -2,579.5% | -1,086.3% | -2,159.0% | -391.1% | 48.3% | 32.6% | -1,557.4% | -819.2% | -658.4% |
| ROE % | 101.4% | 64.7% | -41.2% | -41.7% | - | 24.8% | -38.7% | -45.4% | -57.2% |
| ROCE % | - | -78.2% | -39.3% | -36.2% | - | 36.4% | -38.5% | -43.2% | -52.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.22% | 20.68M | $223.95M |
| 2 | Arch Venture Management, Llc | 7.50% | 12.69M | $137.48M |
| 3 | Vanguard Portfolio Management LLC | 6.79% | 11.50M | $124.49M |
| 4 | SB Investment Advisers (UK) LTD | 6.47% | 10.95M | $118.57M |
| 5 | State Street Corporation | 5.89% | 9.96M | $107.91M |
| 6 | GSK plc | 5.05% | 8.55M | $92.61M |
| 7 | Vanguard Capital Management LLC | 3.78% | 6.39M | $69.19M |
| 8 | Point72 Asset Management, L.P. | 3.35% | 5.67M | $61.37M |
| 9 | Geode Capital Management, LLC | 1.98% | 3.35M | $36.26M |
| 10 | Dimensional Fund Advisors LP | 1.84% | 3.12M | $33.78M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VIR
Intuit Stock Rallies Pre-Market Today And There’s An Anthropic Connection - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQdEZHVVEzWEdMRXNvdmpOVVBmTVNJLWFhalRzeFQ4bG0zVUZvT3p1a2RWaEZXTDFQWGI4MFJMakZfYk5yUnAxTThhQ1hZSm5zSHd4Y1JKNDhTeWMyQmFzaTlacjlzWUdjcVZHSnMzV2NoaFlIZFI3enQ4MVhxRUM0WUw4T2ROT1h5X3lWZk…
Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQVUQwMmdOVjhYOFRtcThQclh4ZHlpeW1jcTRsSVBGb0dfVV81WHpZc1pPU09QNDdmUDlFbUFBUjhKck8taVhCSVlJanFuVTdVVDBGaUZOM3U2V3N6YjI5MV82VDdsUUxvbWJSSXpCbGZBM3J1VzBuM0F6Qks5X3phRHF5VzNpUkpTc1ZsUW…
How (VIR) Movements Inform Risk Allocation Models - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPVFFaVEk5N1pSSURXUnJsczVuQXVsN1hib2V1QUR1dHhfMWFhdldUTWhodEtic0lock9UakZHRUEybUdZMVlFNnQ4Y0JHeUVQM2hjOW0wX0VHTzJSUE5lNTJid0RFeFZJaWM1VWdhbVBWUHJUeFJyUzlaQXBnQjA1ejJmQ3VRMDQzTm5TZm…
Vir Biotechnology stock hits 52-week high at 11.66 USD - Investing.com
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQUzc2U1NSdXZBeDhDSHRVMS1abnJzRjRiV1g4Z1dVc1UzT29jWGI0SWtVbmwxZmluNF8zV3JfZmowU3dXV1l3Snl5VmVBdk5yUTV3QnNOT1d6bXZaVU10cTJ6c1dnT1kxb1BIZGk3ejk5M3ZJejBSeFJLb2ZDcXJGdm14ZG9NZnRUOXl5dV…
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxObFlKOVRaUmp2TlJndFh5RlJHMU1EOFBBS3A1Wjh5bi1ZcU93dU5GYmpaQUdWdVNPcTUwcGNDa0N0UTJYRFRQa2toMTBILXotOC1HWXkwdG9RaHdXWDYxbmV2WGpLZDZsUWdEMkl5VVNHZXRCblB3UU5ub3pFeHVzQTFvOWE1TV9CNmF3Rz…
Vir Biotechnology CEO to speak at Morgan Stanley conference Sept. 14 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQRzBPUUZFQUVwMy1wX1J3VkpPanRWUHZ3WENaZzA0amtzbFVWYWZ0cDJYUTlxTV90YVFULURTN0JYblFhbHlpYVpVRFk0UXdkbEI2eXp5SGpUY28zd0U2MFhMcE4tLTFVMXNBYm9BWHFjVlNZeUtxSWJzaVdfdXNjRVJGaWUwSWRxM2Zsel…
VIR — Frequently Asked Questions
What is the current share price of Vir Biotechnology, Inc. (VIR)?
As of 2026-09-07 16:24 PDT, Vir Biotechnology, Inc. (VIR) trades at $11.38 on NasdaqGS. Its 52-week range is $4.36 to $11.63.
What is the market capitalisation of VIR?
Vir Biotechnology, Inc. (VIR) has a market capitalisation of $1.93B on NasdaqGS.
What is the P/E ratio of VIR?
VIR trades at a trailing price-to-earnings (P/E) ratio of -6.43. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.75.
What is the return on equity (ROE) of VIR?
VIR has a return on equity (ROE) of -26.08%. Its return on capital employed (ROCE) is -52.69%.
Is VIR a good stock to buy?
This page provides a data-driven analysis of Vir Biotechnology, Inc. (VIR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.